Laura Kennedy is an Oncology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372324405
Telephone
615-936-2000Provider last certified this registry record 19 Sept 2023.
Clinical trials
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Sponsor: Vanderbilt-Ingram Cancer Center
- Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment
Sponsor: Laura Kennedy
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2025$578,023R01CA273246 - Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2024$546,296R01CA273246 - Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
Vanderbilt University Medical Center
FY2023$510,310R01CA273246
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”